Panteleeva G P, Minsker E I, Tsirkin S Iu, Beliaev B S, Lukanina S K
Zh Nevropatol Psikhiatr Im S S Korsakova. 1980;80(5):748-54.
A possibility has been studied of using certain clinical and pharmacokinetical parameters for the individual prediction of chlorpromazine efficacy in 25 schizophrenic patients with different degrees of progression. It was established that the most informative clinical parameter of a successful treatment prognosis is the disease course, polymorphic character of the structure in the prevalent syndrome with a generalization of disorders and an absence of delusional systematizations, a relatively low level of negative personality changes, alternating character of affective disorders in the initial stage of the disease and a certain development of the mental state after a single administration of a control dose of chlorpromazine. Assessment of the pharmacokinetic parameters was provided by the use of a mathematical modelling of pharmacokinetic processes. The most informative pharmacokinetic parameter was the period of half-life of the drug and the constant of the penetration rate from the intestine into blood.
研究了利用某些临床和药代动力学参数对25例不同病程进展程度的精神分裂症患者进行氯丙嗪疗效个体预测的可能性。结果表明，成功治疗预后最具信息量的临床参数是病程、普遍综合征中结构的多形性特征、障碍的泛化和妄想系统化的缺失、负面人格变化相对较低水平、疾病初期情感障碍的交替特征以及单次给予氯丙嗪对照剂量后精神状态的一定发展。通过药代动力学过程的数学模型对药代动力学参数进行评估。最具信息量的药代动力学参数是药物的半衰期和从肠道到血液的渗透速率常数。
